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OBJECTIVES In this study, the feasibility of delivering and enhancing the uptake of vascular endothelial
growth factor (VEGF) into the intact endothelium by using ultrasound (US) facilitation was
determined.
BACKGROUND A limitation of tissue-targeted drug delivery is the need for direct arterial cannulation. We
postulate a mechanism by which agents injected intravenously may be targeted to a tissue
using US and ultrasonic contrast agents.
METHODS We used a rat model to test the ability of US and an ultrasonic contrast agent perflurocarbon
exposed sonicated dextrose albumin (PESDA) to increase uptake of VEGF in the myocar-
dium. Continuous wave Doppler US (0.6 W/cm2 at 1 MHz for 15 min) was applied to the
chest wall overlying the myocardium during intravenous injection with either VEGF
(100 mg/kg) alone or a combination of VEGF and PESDA (0.1%). Control rats had VEGF
infused without US or PESDA. The VEGF uptake was measured quantitatively in the heart,
lung, liver and kidneys by enzyme-linked immunosorbent assay (ng/g of tissue) and
morphologically by fluorescence microscopy.
RESULTS There was an eight-fold increase in VEGF uptake in the heart by US alone (16.86 6 1.56
vs. 2.11 6 0.953 ng/g of tissue, p , 0.0001) and a 13-fold increase with US 1 PESDA
(26.78 6 2.88 vs. 2.11 6 0.953 ng/g of tissue, p , 0.0001) compared with control rats.
Fluorescence microscopy revealed deposition of VEGF in the endothelium of small
intramyocardial arterioles.
CONCLUSIONS These results show a marked increase in endothelial VEGF uptake with US and US 1
PESDA. Thus, US may be used to augment endothelial VEGF uptake 10-fold to 13-fold.
(J Am Coll Cardiol 2000;35:1678–86) © 2000 by the American College of Cardiology
Ischemic heart disease is the major cause of morbidity and
mortality in the U.S. With the aging of the population and
with the increased survival of patients with coronary artery
disease, increasing numbers of patients have diffuse coronary
artery disease that is not amenable to traditional methods of
revascularization, that is, bypass surgery or angioplasty (1).
Newer methods of therapy are being investigated in these
patients, including transmyocardial revascularization, percu-
taneous transmyocardial revascularization and infusion of
growth factors such as vascular endothelial growth factor
(VEGF) and fibroblast growth factor to promote angiogenesis.
Vascular endothelial growth factor is a 46-kDa glyco-
protein that is a mitogen for endothelial cells (2). A number
of observations point to the importance of VEGF in
angiogenesis. Vascular endothelial growth factor and its
receptors are expressed in cells surrounding the expanding
vasculature during embryonic development, and VEGF is
predominantly produced in tissues acquiring new capillary
networks (3,4). Furthermore, the ability of VEGF to induce
formation of collateral circulation has been demonstrated in
a rabbit ischemic leg model (5) and human peripheral
vascular disease (6). More recently, VEGF was adminis-
tered by intracoronary infusion in a group of patients with
reversible thallium defects who were not candidates for
coronary artery bypass grafting or percutaneous transluminal
coronary angioplasty (CABG or PTCA) (7). These ap-
proaches may usher in a new era of treating vascular disease
both coronary and peripheral by improving blood supply
with formation of new blood vessels.
A major limitation of current methods of tissue-targeted
drug delivery involves invasive arterial cannulation. We
hypothesized that drugs injected via a peripheral vein may
be targeted to a particular tissue using ultrasound (US) and
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ultrasonic contrast agents. We sought to test the hypothesis
that US with or without contrast microbubbles could
enhance uptake of VEGF to the myocardium using both
Langendorff and intact rat models. We also studied varying
power levels of US to determine the relationship of US
acoustic power to uptake of VEGF.
METHODS
In vitro studies. A Langendorff rat heart preparation was
used to test the effect of US with and without contrast agent
on endothelial uptake of VEGF.
LANGENDORFF RAT HEART PREPARATION. Sixteen week-
old male Wistar-Kyoto rats (Taconic Farm; Germantown,
New York) were anesthetized with sodium pentobarbital
(20 mg/kg intraperitoneally). After intravenous administra-
tion of sodium heparin (2,000 IU), the hearts were removed
and rapidly immersed in ice-cold Krebs-Henseleit bicarbon-
ate (KHB) solution. After trimming and weighing, the
hearts were mounted on a non recirculating Langendorff
apparatus and perfused at 80 mm Hg (coronary perfusion
pressure) at flow rates of 2.5 ml/min while the temperature
was maintained at 37°C. Perfusion media (KHB) was pH
balanced and iso-osmolar to plasma. The medium was
equilibrated by continual gassing with 95% O2 and 5%
CO2, and adjusted to pH of 7.35 to 7.40 for the duration of
the experiment. All animal experiments were approved by
the Animal Review Committee and the Research and
Programs committee of the Institution.
PERFLUOROCARBON-EXPOSED SONICATED DEXTROSE AL-
BUMIN. Perfluorocarbon-exposed sonicated dextrose albu-
min (PESDA), a solution of microbubbles containing per-
flurocarbon (,6 mm in diameter) enveloped in an albumin
shell, is produced by sonicating a solution of dextrose
containing albumin and perflurocarbon gases (8). Three
parts of 5% dextrose and one part of 5% human serum
albumin (total 16 ml) were drawn into a 35-ml syringe
(Monoject). Each dextrose albumin sample was hand agi-
tated with 8 6 2 ml of a fluorocarbon gas (decafluorobu-
tane), and the sample was then exposed to electromechan-
ical sonication at 20 kHz for 80 6 5 s. The maximal energy
output from the sonicating horn was 550 W. Energy output
was manually adjusted using a digital scale to achieve 25% 6
3% of the maximum output during the entire sonication
time (124 6 15 W). During this process, the albumin
formed bubbles creating a relatively rigid shell. The mean
size of the PESDA microbubbles produced in this manner
was 4.7 6 0.2 mm. The PESDA is in the form of
microbubbles both at room temperature and at 37°C in the
body (8). The PESDA was obtained from one of the
coauthors (T.P.). The safety of PESDA has already been
demonstrated in humans (8).
FLUORESCEIN LABELING OF VEGF. One hundred micro-
grams of fluorescein isothiocyanate (FITC) mixture (Cal-
biochem) was mixed with 500 mg of rhVEGF (recombinant
human VEGF) to achieve a conjugation ratio of 5:1
(protein:FITC) and incubated at room temperature for 2 h.
The mixture was dialyzed overnight with a dispodialyzer
(Spectrapor) to remove free FITC molecules. Fluorescein-
labeled VEGF was mixed with PESDA at room tempera-
ture for 60 min prior to injection into animals.
STUDY PROTOCOL. Recombinant human vascular endothe-
lial growth factor (rhVEGF165; Genentech Inc.; San Fran-
cisco, California) alone or in combination with PESDA
(0.1%) was infused into the aorta via a cannula. In the group
receiving VEGF with PESDA, VEGF was preincubated
with PESDA for 60 min at room temperature. The perfu-
sion rate (precalibrated before each use) was maintained at
2.5 ml/min using a perfusion pump (Pharmacia & Upjohn;
Bridgewater, New Jersey). Animals were randomized into
six groups. Then 100 mg/kg of VEGF labeled with fluores-
cein (FITC labeling kit; Calbiochem; La Jolla, California)
was infused over 15 min in appropriate groups. The dose of
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
ELISA 5 enzyme-linked immunosorbent assay
FITC 5 fluorescein isothiocyanate
KHB 5 Krebs-Henseleit bicarbonate
PBS 5 phosphate buffered saline
PCNA 5 proliferating cells
PESDA 5 perfluorocarbon-exposed sonicated dextrose
albumin
PTCA 5 percutaneous transluminal coronary
angioplasty
rhVEGF 5 recombinant human VEGF
US 5 ultrasound
VEGF 5 vascular endothelial growth factor
vWF 5 von Willibrand factor
Table 1. Relationship Between Ultrasound Power and Endothelial Vascular Endothelial Growth Factor Uptake With a Plateau
Beyond 0.6 to 0.8 W/cm2
Group 1
(n 5 2)
Group 2
(n 5 2)
Group 3
(n 5 2)
Group 4
(n 5 4)
Group 5
(n 5 2)
Group 6
(n 5 2)
Ultrasound (W/cm2) — 0.2 0.4 0.6 0.8 1.0
MPa — 0.164 0.194 0.328 0.394 0.419
VEGF (ELISA) 2.35 6 0.67 9.37 6 1.98 18.58 6 2.46 23.12 6 3.95 25.46 6 2.78 26.48 6 3.98
ELISA 5 enzyme-linked immunosorbent assay; Mpa 5 peak negative pressure; VEGF 5 vascular endothelial growth factor.
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VEGF is based on previous animal experiments (9–13).
During the infusion of VEGF, US energy (1.0 MHz at
0.6 W/cm2 power or 0.328 peak negative pressure [MPa])
was delivered to the myocardium directly with a sonicator
US generator, 1.9 cm in diameter (model ME 720; Mettler
Electronics; Anaheim, California) for 15 min. This is the
expected time that PESDA remains in circulation after an
intravenous injection (8). The myocardial area covered by
the US probe was approximately 0.5 to 0.6 cm2. The peak
negative pressure generated was measured with a hydro-
phone (Sonic Technologies, model S/N804-077; Grass
Valley, California) in our laboratory. The acoustic pressure
measurement was made by placing a calibrated membrane
hydrophone (spot size approximately 0.5 mm) in front of
the transducer and recording the amplitude of the received
signal. A table was then used to calculate the acoustic
pressure from the received voltage. After the treatment
period, the myocardium was perfused with fresh KHB
solution for 5 min to clear any unbound intraluminal
collections of PESDA or VEGF. Uptake of VEGF was
assessed quantitatively using enzyme-linked immunosor-
bent assay (ELISA) and fluorometry, and morphologically
by fluorescence microscopy (Fig. 1). The effect of US on
endothelium was assessed by electron microscopy.
To determine the optimum ultrasonic acoustic power
for enhancement of VEGF uptake, US was applied with
various acoustical outputs (0.2, 0.4, 0.6, 0.8, and
1.0 W/cm2) and VEGF uptake measured in the myocar-
dium (Table 1). For the dose response experiments, VEGF
was coadministered with PESDA.
TISSUE COLLECTION, PREPARATION AND HISTOLOGY. Af-
ter perfusion was discontinued, the heart was removed and
a coronal section of the midventricular region was excised,
mounted in Tissue Tek optimal cutting temperature com-
pound (Miles Inc.; Elkhart, Indiana), immediately frozen
under liquid nitrogen and stored at 280°C. Frozen sections
were cut at 5 mm for fluorescence microscopy while an
adjacent section (2.5 mm) was stained with hematoxylin-
eosin. One piece was preserved in phosphate buffered saline
(PBS) while the other was immediately submerged into
liquid nitrogen and stored for frozen sections for micros-
copy. Frozen sections were viewed immediately using a
fluorescence microscope (Dialux 22; Leitz, Germany), and
morphologic localization of FITC-labeled VEGF was ex-
amined. Photographs of the fluorescent sections were taken
(Kodak Elite II 400 ASA film).
ELISA. For ELISA, a section of the heart muscle was
homogenized in lysis buffer (0.1 M sodium carbonate at a
pH of 9.6, 0.1% NP-40, 1 mM leupeptin, 1 mM phenyl-
Figure 1. Fluorescent microscopy (1003) revealed marked enhancement of VEGF uptake with US and PESDA. A) reveals minimal
endothelial uptake of VEGF after intravenous injection of VEGF without ultrasound. B) reveals minimal fluorescence in the endothelium
after injection of buffer solution without VEGF. C) reveals significant deposition of VEGF in the endothelial cells with PESDA and US,
using a Langendorff preparation. D) reveals significant deposition of VEGF in the endothelial cells with PESDA and US, after intravenous
injection in short-term in vivo experiments. E) reveals significant deposition of VEGF in the endothelial cells with US alone, using a
Langendorff preparation. F) reveals significant deposition of VEGF in the endothelial cells with US alone, after intravenous injection in
short-term in vivo experiments.
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methane sulphonyl fluoride, and 10 ml/ml ethylenediamine
tetraacetic acid). The homogenate was then centrifuged at
750g, at 4°C for 6 min. Protein G microtiter plates (Pierce
Immunochemicals; Rockford, Illinois) were coated with
monoclonal antibody to VEGF (Genentech, Inc.). Super-
block buffer (Pierce) was added to these plates and incu-
bated for 60 min, to reduce nonspecific binding. The
samples and VEGF standards (R & D Systems) were
diluted in carbonate buffer and added to these plates. The
samples were incubated at 37°C for 2 h. Standards consisted
of two-fold dilutions of rhVEGF165, starting at 0.3 ng per
well to 38.4 ng per well. The samples were removed and the
wells were washed in washing buffer (PBS at a pH of 7.4,
0.05% polysorbate 20 [Tween 20]). A specific polyclonal
antibody to VEGF (R & D Systems; Minneapolis, Minne-
sota) labeled with horseradish peroxidase was added to the
wells and incubated for 1 h. The wells were again washed
with washing buffer. One hundred microliters of a 50:50
mixture of hydrogen peroxide and tetramethylbenzidine was
added to the wells. To this, 100 ml of 0.01 N HCl was
added, and optical density was determined by spectropho-
tometry at 450 nm using a spectrophotometer (Beckman
DU-64). A standard curve was plotted using known
concentrations of standard VEGF and the amount of
VEGF in the samples was extrapolated from this stan-
dard curve using a polynomial regression equation. All
ELISA results are expressed as nanograms of VEGF per
gram tissue. The accuracy of the assay was ascertained by
adding known amounts of VEGF to the wells as control.
ELECTRON MICROSCOPY. Transmission electron micros-
copy was performed at magnifications between 2,8003 and
10,0003, on sections of the left ventricle adjacent to the US
transducer. After treatment with US and perfusion of KHB
solution, the hearts were randomized into three fixation
protocols. Control hearts (n 5 2) were fixed without
application of US or PESDA. In treated groups (n 5 2 for
each group), hearts were fixed during application of US (0.6,
0.8, 1.0 W/cm2) and with or without 0.1% PESDA added
to the buffer. In all groups, 0.1 M phosphate-buffered 2.5%
glutaraldehyde in sucrose was infused for 5 min at
2.5 ml/min to fix the myocardium. Twelve sections from
each ventricle were analyzed.
In vivo experiments (short-term). Sixteen week-old
Wistar-Kyoto rats were anesthetized with 0.2-ml intraperi-
toneal pentobarbital. Appropriate amounts of VEGF
(100 mg/kg) and PESDA were injected in 0.2-ml volume
using a 25-gauge needle into the femoral vein. The dose of
PESDA was based on a 15-ml blood volume, 10 ml/min
cardiac output and an expected in vivo PESDA dose to
reach 0.1% concentration in circulation. Ultrasound
(0.1 MHz at 0.6 W/cm2 power or 0.328 peak negative
pressure amplitude [MPa]) was applied directly to the chest
wall for 15 min. The animals were killed with 0.8 ml
intraperitonial pentobarbital sodium (Nembutal), and the
heart, liver, kidneys and the lungs were removed. The heart
was perfused with Krebs buffer in a Langendorff preparation
for 5 min to clear the intravascular space of blood and
unbound VEGF. The amount of VEGF taken up by the
myocardium, liver, kidneys, and lung was measured quan-
titatively by ELISA and morphologically by fluorescence
microscopy.
In vivo experiments (long-term). Sixteen week-old spon-
taneously hypertensive rats (Taconic Farm; Germantown,
New York), fed high-cholesterol diet, were anesthetized
with 0.2-ml intraperitoneal pentobarbital. Appropriate
amounts of VEGF (100 mg/kg) and PESDA were injected
in 0.2-ml volume using a 25-gauge needle into the tail vein,
and US was applied to the chest wall for 15 min as described
above. Vascular endothelial growth factor was injected once
a week for four weeks. The animals were euthanasized with
0.8-ml intraperitonial pentobarbital (Nembutal), and the
hearts were removed. The hearts were fixed in formalin for
immunohistochemistry. The different groups are shown in
Table 2.
Immunohistochemistry. SAMPLE PREPARATION. The
formalin-fixed rat hearts were taken and a 2-mm-thick cross
section was taken through the mid portion of the heart,
allowing visualization of the right ventricle, left ventricle,
coronary arteries and septum. The tissue was then processed
Table 2. Enhanced Endothelial VEGF Uptake With US and Contrast Agent After Intravenous
Injection*
Group 1
(n 5 4)
Group 2
(n 5 4)
Group 3
(n 5 4)
Group 4
(n 5 4)
PESDA 2 2 1 1
Ultrasound 2 1 2 1
VEGF 1 1 1 1
Heart (VEGF ng/g) 2.11 6 0.953 16.86 6 1.564* 2.01 6 0.895 26.78 6 2.880*
Lung (VEGF ng/g) 2.10 6 0.094 4.14 6 0.186 2.21 6 0.078 4.89 6 0.102
Liver (VEGF ng/g) 2.52 6 0.056 2.56 6 0.065 2.39 6 0.049 2.47 6 0.067
Kidney (VEGF ng/g) 2.36 6 0.198 2.96 6 0.112 2.03 6 0.137 2.71 6 0.239
*As measured by enzyme-linked immunosorbent assay in an in vivo model.
PESDA 5 perfluorocarbon-exposed sonicated dextrose albumin; VEGF 5 vascular endothelial growth factor.
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and paraffin embedded according to standard laboratory
procedures. Five sections were cut from each block at 4 mm,
collected onto electrostatically charged slides and baked at
60°C for 60 min. Two sections were stained with
hematoxylin-eosin and Movat pentachrome, while the re-
maining three were stained immunohistochemically for
PCNA (proliferating cells), von Willibrand factor (vWF)
for endothelial cells and alpha-smooth muscle actin for
smooth muscle cells as described (14).
IMMUNOHISTOCHEMICAL STAINING PROCEDURE. The
paraffin was removed from the baked tissue sections in three
changes of xylene, and the tissue was hydrated through graded
alcohols before rinsing in PBS. Immunohistochemical staining
was performed (Jung Histostainer; Leica, Illinois), with pro-
cessing occurring at 30°C. The first stage of the procedure
involved the application of 1% hydrogen peroxide solution in
methanol for 5 min to remove any endogenous peroxidase
present in the tissue section. For mouse monoclonal primary
antibodies (PCNA and alpha-smooth muscle actin), a block-
ing solution comprising a 1:10 dilution of normal rabbit serum
(Dako; Carpenteria, California) in PBS was then added for
10 min before application of the primary antibody. The
required dilutions of antibody were prepared using 1% bovine
serum albumin in PBS. Incubation occurred at 30°C for
60 min, and a 1:200 dilution of biotinylated rabbit antimouse
polyclonal antibody (Dako) was added for a further 30 min.
The antibody was labeled using an Elite avidin/biotin/
peroxidase complex (Vector Laboratories; Burlingame, Cali-
fornia) applied for 30 min. The final stage comprised the
addition of 3,3-diaminobenzidine as a chromogen (DAB Kit;
Vector Laboratories). Between each step, the slides were rinsed
twice for 2 min in PBS. For the polyclonal antibody (vWF), a
similar procedure was followed except that normal swine serum
instead of rabbit serum was used as a blocking agent, and
biotinylated swine antirabbit polyclonal antibody was used as
the link. Following staining, the sections were rinsed in
distilled water, counterstained with hematoxylin, dehydrated
and cleared in xylene; a coverslip was placed on the section.
The negative control sections were treated in an identical
manner to the test tissue except that 1% BSA in PBS was
added instead of primary antibody. Cell counts are expressed as
number of positively stained cells per 2003 magnification field.
Ten fields were counted on each slide. Isolated endothelial and
smooth muscle cells (not associated with a vascular lumen)
were counted to determine migrating cells.
Statistics. Data are expressed as mean 6 SD. Groups were
compared using an analysis of variance and contrasts for
pairwise comparisons were made using Sheffe’s post hoc test
(Statistica for Windows 4.0; Statsoft, Inc.). A p , 0.01 was
used to determine statistical significance.
RESULTS
In vitro experiments. Combinations of VEGF, PESDA
and US were used and results are summarized. Using
ELISA, there was an eight-fold increase in VEGF taken up
by the myocardium using US alone (19.23 6 1.78 vs.
2.35 6 0.67 ng/g of tissue, p , 0.0001) and a ten-fold
increase with the combination of PESDA and US (23.12 6
2.95 vs. 2.35 6 0.67 ng/g of tissue, p , 0.00001).
Fluorescent microscopy revealed a marked increase in
deposition in VEGF with US alone (Fig. 1E) and with the
combination of US and PESDA (Fig. 1C). Vascular endo-
thelial growth factor is predominantly detected lining the
endothelium of intramyocardial arterioles as demonstrated
by hematoxylin-eosin staining of an adjacent section
(Fig. 2).
Determination of optimum power. Table 1 shows the
response of incremental US power on uptake of VEGF.
There was a significant increase in VEGF uptake with
combination of US and PESDA at all power levels of US
energy compared with controls. There was a dose-
dependent increase in the amount of VEGF uptake with
increasing power until 0.8 W/cm2, with a subsequent
plateau. There was no significant increment in VEGF
uptake beyond a power level of 0.6 W/cm2 (Table 1).
Electron microscopy. As cavitational and thermal effects
of US are more evident when US power is raised, it was
necessary to determine whether deleterious effects were
produced at power levels that enhanced the uptake of
VEGF with or without PESDA. When US was applied at
1.0 W/cm2 (0.419 MPa) for 15 min with or without
PESDA, severe coagulative necrosis (swollen cells, de-
creased optical density of the cytoplasm, fatty changes in
cytoplasm, condensation of nuclear chromatin and dissolu-
tion of the nucleus by karyolysis) of the small capillaries was
detected (Fig. 3A). In addition, large gaps appeared be-
tween endothelial cells, exposing the subendothelial matrix.
These changes were less pronounced with a power of
0.8 W/cm2 (0.394 MPa) as seen in Figure 3B, and no
such changes were seen in hearts exposed to 0.6 W/cm2
(0.328 MPa) (Fig. 3C). Figure 3D shows a section from a
control rat heart.
Figure 2. Hematoxylin-eosin staining of an adjacent section re-
vealed that the fluorescein-labeled VEGF is predominantly depos-
ited in the endothelium of intramyocardial arterioles (1003).
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In vivo experiments (short-term). The different groups
for in vivo studies are summarized in Table 2. There was
approximately an eight-fold increase in VEGF uptake by
US alone (16.68 6 1.56 vs. 2.11 6 0.953 ng/g of tissue, p ,
0.0001) and a 13-fold increase in uptake with PESDA and
US (26.78 6 2.88 vs. 2.11 6 0.95 ng/g of tissue, p ,
0.00001). Fluorescent microscopy revealed that most
VEGF is taken up by the arterial wall. Figure 1D shows
enhancement of VEGF uptake by US and PESDA, and
Figure 1f shows enhancement with US alone in the endo-
thelium by intramyocardial arterioles.
In vivo experiments (long-term). There was approxi-
mately a four-fold increase in endothelial cell count
(17.91 6 1.63 vs. 4.83 6 0.89, p , 0.0001) in the VEGF 1
US group as compared with VEGF administration alone, as
measured by vWF immunohistochemistry and three-fold
increase in smooth muscle cell count (12.70 6 2.47 vs.
3.41 6 0.67, p , 0.001), as measured by smooth muscle cell
actin antibody. There was no significant increment in
endothelial or smooth muscle cell count with the combina-
tion of US and PESDA compared with US alone. Figure 4
shows the vWF and smooth muscle cell immunohistochem-
istry in the control and US groups. There was no difference
in PCNA count between the groups.
DISCUSSION
Summary of results. This study shows a significant in-
crease in endothelial uptake of VEGF with US alone or a
combination of US and PESDA. The optimum acoustic
power for enhancement of VEGF uptake was 0.6 to
0.8 W/cm2. Commercial echocardiography machines in
clinical use deliver an acoustic output up to 0.44 W/cm2 in
the pulsed and color Doppler mode (15). In our study, even
with an acoustical output within the limits of clinical
echocardiography machines, there was an eight-fold in-
crease in VEGF uptake. There was some increase in uptake
in the lung with US related probably to US scatter while
delivering US to the heart.
Review of the literature. A number of therapeutic modal-
ities currently involve the delivery of medications directly to
the diseased tissue rather than systemically. Takeshita et al.
Figure 3. A) shows extensive coagulative necrosis and endothelial disruption with US power of 1.0 W/cm2 without PESDA (4,8003).
B) shows endothelial pore formation with US power of 0.8 W/cm2 without PESDA (5,4003). C) (8,0003) shows no significant
endothelial changes with US power of 0.6 W/cm2 as compared with control rat heart sections. D) shows a control rat heart section
(4,8003).
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(5,16) have shown that VEGF administered locally to
ischemic muscle in patients with peripheral vascular disease
via the artery perfusing that area results in angiogenesis and
improvement in blood supply. Recently, Schumaker et al.
(17) applied VEGF locally to ischemic muscle during
coronary artery bypass surgery with significant improvement
in perfusion. The ability of VEGF to induce formation of
collateral circulation has been demonstrated in a rabbit
ischemic leg model (4) and human peripheral vascular
disease (5). More recently, VEGF was administered by
intracoronary infusion in a group of patients with reversible
thallium defects who were not candidates for CABG or
PTCA. There was overall improvement in nuclear perfusion
scans in these patients (6). However, one of the major
limitations of this approach is the necessity of either invasive
arterial cannulation of a diseased artery with all the risks
involved or open heart surgery as done by the German group
(17). Peripheral intravenous injection without myocardial
targeting may induce undesirable angiogenesis and vascu-
larity in other organs, as angiogenesis with VEGF has also
been described in the absence of ischemia (18). Also there is
an approximately six-fold increase in VEGF receptor up-
regulation with hypoxia-ischemia (19) and this may not be
enough to increase VEGF uptake sufficiently by itself after
systemic administration to cause adequate angiogenesis. By
targeting VEGF to specific tissue, lower doses of this agent
may be used with decreased risk of side effects such as
hypotension or angiogenesis in nonischemic tissue and with
increased uptake to the ischemic site. The approach dis-
cussed in this article is a noninvasive method to direct
delivery of a therapeutic agent to a specific tissue.
Mechanism of US enhancement of VEGF uptake. Vas-
cular endothelial growth factor is known to bind serum
proteins (8) and we postulated that one of the binding
proteins is albumin. It has previously been demonstrated
that the ability of albumin to bind oligonucleotides remains
intact in PESDA (20). The basic hypothesis of the study
was that by destroying microbubbles containing VEGF in
the coronary circulation, a large amount of VEGF would be
released into the coronaries and taken up by the heart.
However, this hypothesis failed to explain the phenomenon
of significant increase in VEGF uptake with US alone that
we observed. Perfluorocarbon-exposed sonicated dextrose
albumin had minimal incremental effect on enhancing
VEGF uptake. Most of the effect appears to be due to US
energy, which may be locally enhanced by the presence of
“acoustically active” microbubbles. Ultrasound-mediated
enhancement of transfection has been reported in the
literature (21–24) and is attributed to ultrasonic cavitation
Figure 4. Immunohistochemistry showed marked increase in endothelial cell and smooth muscle cell count (not associated with a vascular
lumen) in groups treated with US during administration of VEGF compared with groups treated with VEGF alone. A) shows endothelial
cells as shown by vWF staining in a rat heart from an animal treated with VEGF alone and B) shows endothelial cells in a rat heart treated
with VEGF 1 US. C) shows smooth muscle cells in a rat heart from an animal treated with VEGF alone and D) shows a rat heart from
an animal treated with VEGF 1 US. Positively stained cells were counted at 2003.
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of cells. Since the transfected cells went on to express the
transfected gene, it appears that US at 1 to 2.25 MHz did
not cause any irreversible damage to the cellular machinery.
We have previously reported more than 10-fold increase in
endothelial uptake of oligonucleotides with US alone (25).
Reversible membrane damage with resealing of the holes (or
pores) has been reported with US (23). Electron microscopy
of the rat heart during application of US revealed disruption
or pore formation of the membrane of the endothelial cells
as well as increased gap between endothelial cells with an
acoustic power of 0.8 to 1.0 W/cm2. However no structural
changes were evident with a power of 0.6 W/cm2, which
was the power used for experiments in our study. It is
conceivable that there is micropore formation or increased
permeability with a power of 0.6 W/cm2 that could not be
detected by TEM at the magnification used by us and that
facilitated endothelial VEGF uptake. The mechanism of
US-facilitated enhancement is not simply the bursting of
microbubbles to deposit therapeutic agents. Instead US is
likely to be actively involved in a more complex interplay
among the therapeutic substance, echocontrast agent, the
nature of the US energy and the target tissue characteristics.
It is also possible that VEGF is combining with the albumin
in the echocontrast mixture, which then binds to the
endothelial surface. It has been shown previously that
albumin is incorporated into the luminal glycoprotein sur-
face of vascular endothelium as a means to augment resis-
tance to solute flux (26). The exact mechanism, however,
remains to be determined. Skyba et al. (27) have demon-
strated rupture of #7-mm microvessels (mostly capillaries)
with microbubble destruction during US exposure. Based on
this, Price et al. (28) have devised an elegant model of
tissue-targeted delivery of colloidal particles and red blood
cells by targeted microbubble destruction with US.
Conclusions. It should be noted that we have not demon-
strated actual binding of VEGF to PESDA and it is
possible that an alternative mechanism may explain the
enhancement of VEGF uptake with PESDA. A previous
report showed that there was marked enhancement of
transfection of a plasmid DNA into cultured cells by a
combination of microbubble (albunex) and US, suggesting
that microbubbles may play a role in reversible pore forma-
tion in endothelial cells during the process of cavitation
(sonoporation) (23). It is conceivable that the incremental
effect of PESDA with US seen in these studies is due to
more efficient sonoporation rather than binding of VEGF.
Study Limitations. We used spontaneously hypertensive
rats for the long-term experiments rather than the Wistar-
Kyoto rats, as myocardial ischemia has been reported in
spontaneously hypertensive rats. Studies in a variety of
animal models using VEGF have shown angiogenesis only
in the presence of ischemia (29,30). To demonstrate the
biological effects of VEGF, we wanted to use an animal
with some degree of myocardial ischemia. Our weekly
injections of VEGF for four weeks in a spontaneously
hypertensive model revealed approximately a four-fold in-
crease in endothelial and smooth muscle cell count without
a change in PCNA, suggesting that the increased cell count
is due to cell migration rather than proliferation. During
angiogenesis, migration always precedes proliferation by
approximately 24 h (31,32), and it is possible that we killed
the animals prior to the stage of proliferation. This does
demonstrate that the VEGF delivered using this technique
is biologically active. Although ischemia has been demon-
strated in SHR hearts (33), it is not a well characterized
model of ischemia. A longer-term in vivo experiment in a
well developed ischemic model needs to be performed to
evaluate the efficacy of delivered VEGF. Another potential
limitation is the need to use a 25-gauge needle for intrave-
nous injections in a rat model as most microbubbles may
have been destroyed and minimized the benefits of PESDA
in the in vivo studies.
Clinical applications. This study needs to be validated in a
larger animal model and eventually in humans. Ultrasound
with or without contrast agents promises to be a feasible way
to target drug delivery to specific organs noninvasively. This
technique may be used not only to deliver drugs to the
myocardium but also may be applied to any organ accessible
to US. The technique described may have a special role in
giving high does chemotherapeutic agents to specific organs
in malignancies to reduce toxic reactions.
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